Black Diamond Therapeutics, Inc.
BDTX
$1.60
$0.010.63%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 3.03M | 5.22M | 9.57M | 6.70M | 5.57M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 15.33M | 18.13M | 22.13M | 20.25M | 20.86M |
Operating Income | -15.33M | -18.13M | -22.13M | -20.25M | -20.86M |
Income Before Tax | -15.99M | -15.56M | -19.91M | -18.23M | -19.41M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -15.99M | -15.56M | -19.91M | -18.23M | -19.41M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -15.99M | -15.56M | -19.91M | -18.23M | -19.41M |
EBIT | -15.33M | -18.13M | -22.13M | -20.25M | -20.86M |
EBITDA | -15.25M | -18.04M | -22.04M | -20.16M | -20.77M |
EPS Basic | -0.28 | -0.28 | -0.36 | -0.35 | -0.38 |
Normalized Basic EPS | -0.15 | -0.17 | -0.23 | -0.23 | -0.24 |
EPS Diluted | -0.28 | -0.28 | -0.36 | -0.35 | -0.38 |
Normalized Diluted EPS | -0.15 | -0.17 | -0.23 | -0.23 | -0.24 |
Average Basic Shares Outstanding | 56.61M | 56.51M | 55.16M | 51.81M | 51.64M |
Average Diluted Shares Outstanding | 56.61M | 56.51M | 55.16M | 51.81M | 51.64M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |